We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies.
In Vivo is part of Pharma Intelligence UK Limited
This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183
Israel's largest pharmaceutical company, Teva Pharmaceutical, is buying US generics company Copley for $220mm, paying $11 a share, a (pr)16.8% premium. Hoechst, which owns 52% of Copley, has agreed to sell its stake. Copley had sales last year of $133.5mm, and its net income was just over $10mm.
Deal Industry
Pharmaceuticals
Generic Drugs
Deal Status
Final
Deal Type
Acquisition
Full Acquisition
Payment Includes Cash
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?